Abstract

Ocular drug targeting is one of the most interesting and challenging research topics due to the presence of natural barriers of the eye that attract pharmaceutical technologists. It is important to treat ocular infections, which are frequently encountered and affect people of all ages, in order to protect the integrity of the eye. For this reason, anti-infective agents used in the treatment of ocular infections are frequently the subject of ocular drug delivery system studies. The ocular bioavailability of anti-infective agents is also increased, thanks to micro and nano-carriers, where the dose strength of drugs and frequency of administration can be reduced. On the other hand, the fact that there are products approved by the USFDA among these delivery systems which have completed clinical phase studies shows that these drug delivery systems are promising in the ocular field.